GlassScriptPhysician profile
Todd Stephen Hendrickson
NPI 1922599422
$1,630.83
in general payments reported to CMS, 2019-2025
18 companies · $893 in 2025
The $893 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.20 · 2020: $27.36 · 2021: $27.80 · 2022: $163 · 2023: $79.42 · 2024: $416 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $300.78 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $227.44 | 2022-2025 | |
| Pfizer INC. | $203.44 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $153.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $122.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.77 | 2023-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.54 | 2025 | Caplyta |
| Abbvie INC. | $90.14 | 2020-2025 | |
| Lilly USA, LLC | $89.28 | 2024-2025 | Mounjaro, Zepbound |
| Nevro Corp. | $45.97 | 2022 | |
| Amgen INC. | $43.91 | 2020-2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $27.59 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $23.22 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $23.18 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.76 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $13.44 | 2024 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.08 | 2022 | |
| Boston Scientific Corporation | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Hendrickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.